PRESIDENT AND FELLOWS OF HARVARD COLLEGE

• TRUSTEES OF BOSTON UNIVERSITY

  UEI THL6A6JLE1S7

  $1.5M

  Subcontractor to this prime · 2 sub-awards · latest Feb 25, 2026

  • Office of Assistant Secretary for Preparedness and Response
  • “THE MYERS LAB HAS DEVELOPED PLATFORM TECHNOLOGY FOR THE RAPID CHEMICAL SYNTHESIS OF POTENT INHIBITORS OF THE BACTERIAL LIPOPROTEIN TRANSPORT COMPLEX LOLCDE, WHICH IS SPECIFIC TO AND ESSENTIAL FOR THE GROWTH OF ENTEROBACTERIACEAE, A FAMILY OF GRAM-NEGATIVE BACTERIA. THE BREVITY OF OUR COMPONENT-BASED SYNTHETIC ROUTE, ITS NOTABLE CONVERGENCE, AND THE FACILITY WITH WHICH NEW LEAD MATTER CAN BE DISCOVERED AND SCALED ALL DIFFERENTIATE OUR PROGRAM FROM PRIOR PROGRAMS TO DISCOVER SMALL-MOLECULE INHIBITORS OF LOLCDE. THERE ARE CURRENTLY NO ANTIBIOTICS APPROVED OR IN CLINICAL DEVELOPMENT THAT TARGET LOLCDE, IN SPITE OF MUCH PRIOR EFFORT. WHAT HAS STYMIED ALL PRIOR PROGRAMS TO DEVELOP SMALL-MOLECULE INHIBITORS OF LOLCDE HAS BEEN THE OBSERVED RAPID ACQUISITION OF BACTERIAL RESISTANCE AGAINST ALL PRIOR LEAD MOLECULES, ARISING FROM SINGLE AMINO ACID MODIFICATIONS WITHIN THESE SINGLE-COPY BACTERIAL GENES (LOLC, LOLD, AND LOLE), WITH ATTENDANT MIC SHIFTS OF >16-128-FOLD VS. WILD-TYPE ENTEROBACTERIACEAE. THIS IS NOT THE CASE WITH OUR MOST POTENT INHIBITORS TO DATE. THESE LOLCDE INHIBITORS ARE WELL DIFFERENTIATED FROM ALL PRIOR SMALL-MOLECULE INHIBITORS OF LOLCDE BY THEIR OBSERVED EXTRAORDINARY POTENCIES AGAINST ENTEROBACTERIACEAE, AND, CRUCIALLY, THE FINDING THAT RESISTANCE DEVELOPMENT REQUIRES MULTIPLE CONCURRENT AMINO ACID SUBSTITUTIONS WITHIN THE LOLCDE GENE TARGETS. IT HAS BEEN SUGGESTED AND EXPERIMENTALLY SUPPORTED BY OTHERS THAT LOLCDE-TARGETING ANTIBIOTICS WILL BE LESS HARMFUL TO THE HUMAN MICROBIOTA, WHILE EFFECTIVELY ADDRESSING PATHOGENS SUCH AS E. COLI, K. PNEUMONIA, S. ENTERICA, AND OTHER ENTEROBACTERIACEAE SPP. RESISTANCE MECHANISMS WHICH PASSIVATE OTHER APPROVED GRAM-NEGATIVE ANTIBIOTICS SHOULD NOT IMPEDE OR RECOGNIZE OUR NEW LOLCDE INHIBITORS, AND PRELIMINARY EVIDENCE SUPPORTS THIS CONTENTION. THE LOCATION OF THE TARGET WITHIN THE PERIPLASMIC SPACE OF THE G-NEGATIVE PATHOGEN IS ANOTHER DIFFERENTIATION FROM EXISTING ANTIBIOTICS, WHOSE TARGETS OFTEN LIE WITHIN THE BACTE”
  • “THE MYERS LABORATORY EXTENSIVELY REDESIGNS NATURAL ANTIBIOTIC SCA¿OLDS THEN PREPARES THEM BY CHEMICAL SYNTHESIS TO ACCESS NEW ANTIBIOTICS E¿ECTIVE AGAINST MULTIDRUG-RESISTANT BACTERIAL PATHOGENS. THE STRATEGY PERMITS SCA¿OLD MODI¿CATIONS THAT CANNOT BE ACHIEVED BY SEMI- SYNTHESIS AND PROVIDES A MEANS TO OVERCOME EXISTING CLASS-BASED RESISTANCE MECHANISMS AS WELL AS BROADEN THE SPECTRUM OF ACTIVITY. RECENTLY, EXPLORATIONS TO EXPAND AND REDE¿NE THE LINCOSAMIDE CLASS HAVE DELIVERED A SET OF PARTICULARLY PROMISING LEAD MOLECULES, COLLECTIVELY TERMED THE OXEPANOPROLINAMIDES (OPPS). OPPS OVERCOME RESISTANCE MECHANISMS THAT RENDER >10 OTHER CLASSES OF RIBOSOME-TARGETING ANTIBIOTICS INACTIVE (INCLUDING LINCOSAMIDES, MACROLIDES, AND OXAZOLIDINONES) AND ARE IMPERVIOUS TO RESISTANCE MECHANISMS THAT DISABLE ANTIBIOTICS WITH DI¿ERENT TARGETS (E.G., CELL-WALL BIOSYNTHESIS INHIBITORS, AND GYRASE AND TOPOISOMERASE INHIBITORS). THE LEAD OPPS ARE POTENT, BROAD-SPECTRUM AGENTS, AND DEMONSTRATE IN VIVO E¿CACY AGAINST MULTIDRUG-RESISTANT (MDR) GRAM-POSITIVE AND GRAM-NEGATIVE ORGANISMS. OPPS SHOW EXQUISITE POTENCY IN VITRO AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, AND ENTEROCOCCUS SPP., INCLUDING STRAINS CONSTITUTIVELY EXPRESSING LINCOSAMIDE RESISTANCE DETERMINANTS. OPPS ALSO POTENTLY INHIBIT MANY HIGH-PRIORITY, MDR GRAM-NEGATIVE PATHOGENS IN VITRO INCLUDING NEISSERIA GONORRHOEAE AND ESCHERICHIA COLI. IN VITRO SAFETY PRO¿LING EXPERIMENTS REVEAL THAT OPPS SELECTIVELY INHIBIT BACTERIAL CELL GROWTH AND SUGGEST THAT THEY MAY O¿ER A LARGE THERAPEUTIC WINDOW. WITH THE SUPPORT OF CARB-X, THIS PROGRAM SEEKS TO PRO¿LE FOUR HIGHLY PROMISING LEAD MOLECULES TO ASSESS THEIR POTENTIAL AS LEAD CANDIDATES FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP). THIS PROGRAM WILL EVALUATE THE LEAD OPPS IN A WELL-DE¿NED SET OF ASSAYS TO FURTHER CHARACTERIZE THEIR SAFETY, E¿CACY, AND PHARMACOKINETIC PROPERTIES. THESE CHARACTERIZATIONS WILL ENABLE OUR GROUP TO EIT”
• UNIVERSITY OF MARYLAND, COLLEGE PARK

  UEI NPU8ULVAAS23 · not in the directory yet

  $586.4K

  Subcontractor to this prime · 1 sub-award · latest Apr 3, 2025

  • Defense Advanced Research Projects Agency
  • “EVERIFY: DARPA PERSISTENT OCEANOGRAPHIC DEVICE POWER (PODPOWER)”
• BROOKHAVEN SCIENCE ASSOCIATES LLC

  UEI R85KZ9JP3NM3

  $125.7K

  Subcontractor to this prime · 1 sub-award · latest Sep 11, 2026

  • Department of Energy
  • “RESEARCH & DEVELOPMENT”

• THE MCLEAN HOSPITAL CORPORATION

  UEI MCKWJYCWNVN3

  $586.8K

  Subcontracted by this company · 1 sub-award · latest Feb 21, 2024

  • Defense Health Agency
  • “THE FOLLOWING SUMMARIZES THE PROPOSED WORK TO BE DONE AT MCLEAN HOSPITAL, HARVARD MEDICAL SCHOOL TEACHING HOSPITAL, UNDER THE DIRECTION OF KERRY RESSLER. I HAVE A COLLECTION OF ~6000 SAMPLES WITH WHOLE-GENOME GENOTYPING DATA AND > 1000 BLOOD SAMPLES DRAWN FROM CIVILIAN PERSONS WHO EXPERIENCED SEVERE TRAUMA. THESE SAMPLES WERE DRAWN AT 8-10AM, FASTING. THESE DATA ARE HIGHLY COMPLEMENTARY WITH THE ARMY DATA FROM FORT CAMPBELL AND THE SYSTEMS BIOLOGY COHORT AND WILL INCREASE THE POWER OF OUR AI/ML DESIGN AND PREDICTION TOOLS. THE COHORT INCLUDES BOTH MALE AND FEMALES, AND EACH PERSON WAS EVALUATED TO DETERMINE THEIR TRAUMA HISTORY (CTQ, TEI, ETC), AND IF THEY DID/DID NOT HAVE PTSD USING A VARIETY OF STANDARDIZED MEASURES (CAPS, MPSS). THE DATA INCLUDES SOME MODERATE TO HIGH THRESHOLD, AS WELL AS SUB-THRESHOLD INDIVIDUALS. THAT STUDY WAS FUNDED BY NIH, AND I AM FREE TO SHARE THESE VALUABLE SAMPLES AND ACCOMPANYING PHENOTYPE DATA WITH APPROPRIATE PROJECTS FOR THOROUGH AND ADDITIONAL ANALYSIS. IN RECONCILE THE DIFFERENCE OF PSYCHOLOGICAL MEASUREMENTS (CAPS VS PCL) BETWEEN COHORTS, ESTABLISH A CONSISTENT DEFINITION OF PTSD CASE/SUBTHRESHOLD AND HIGH/LOW RESILIENCE PTSD (-),PROVIDE CONFIDENCE SCORES OF THE PTSD CATEGORIES FROM THE PSYCH INSTRUMENTS USED TO INCLUDE CAPS, PCL, PSQI, ANXIETY, GAD, BDI, PHQ, AND DRRI_D. WE WILL ALSO WORK WITH THE OTHER GROUPS TO PROVIDE GENETICS AND EPIGENETICS EXPERTISE FOR UNDERSTANDING BIOMARKERS OF TRAUMA-RELATED DISORDERS. WE WILL WORK WITH DR. DOYLE AND THE SYSTEMS BIOLOGY COHORT TO FIRST CLEAN AND ANALYZE DATA OF THESE COMPLEMENTARY COHORTS (DELIVERABLE 1) AND TO PROVIDE AI/ ML APPROACHES TO MAXIMIZE PREDICTIVE INDICATORS ACROSS MILITARY AND CIVILIAN COHORTS (DELIVERABLE 2). TOGETHER THIS WORK WILL CONTRIBUTE TO SECTION 6.3 OF THE OVERALL PROJECT ""ARTIFICIAL INTELLIGENCE MACHINE LEARNING (AI/ML) DESIGN OF PTSD OBJECTIVE INDICATORS, A01-PWS-AIML, THROUGH THE WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) OF THE US DEPARTMENT OF”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.